GEM 231
Alternative Names: PKAI-AS 231Latest Information Update: 20 Jan 2023
At a glance
- Originator Idera Pharmaceuticals
- Developer Aceragen
- Class Antisense oligonucleotides
- Mechanism of Action Protein kinase A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours